Global Alzheimer trial enrollment gaps reflect systemic inequities, ageism, and underfunded community outreach
Original framing: “Clinical trials for Alzheimer’s treatment face global shortage of participants” — The Japan Times
Scientifically, low enrollment reduces statistical power, inflates Type II error risk, and delays validation of biomarkers. Meta‑analyses demonstrate that adaptive trial designs and real‑world evidence can mitigate participant scarcity while preserving rigor. However, the article neglects to discuss these methodological innovations.
The participant shortage in Alzheimer trials is not a neutral logistical flaw but a symptom of entrenched ageism, profit‑centric research models, and historic mistrust rooted in colonial and exploitative practices.
By integrating Indigenous governance, cross‑cultural recruitment tactics, and adaptive scientific designs, stakeholders can transform trials into inclusive, community‑anchored enterprises. Policy levers—such as mandated diversity quotas and public funding for decentralized sites—can re‑balance power between pharmaceutical firms and the populations they serve. Ultimately, reframing trials as reparative public health interventions, rather than market‑driven quests, aligns future therapeutic efficacy with global equity.